Furthermore, the COVID-19 pandemic highlighted vulnerabilities in the global supply chain. Disruptions in the supply of raw materials affected API production, leading to shortages in essential medicines. As a result, many pharmaceutical companies are now reconsidering their supply chain strategies and investing in local manufacturing capabilities to mitigate future risks.
In recent years, sustainability has become a paramount concern for both consumers and manufacturers. The pharmaceutical industry has begun to focus on green chemistry practices to reduce the environmental impact of API manufacturing. This includes developing processes that minimize the use of hazardous substances and reduce waste.